By Paul Ziobro
Ascendis Pharma said the Food & Drug Administration will review an application to expand the use of its drug to treat growth hormone deficiency to adults.
The Danish biopharma company on Thursday said the FDA accepted its supplemental biologics application in adult growth hormone deficiency for TransCon hGH, which is marketed as Skytrofa for pediatric patients.
"This marks another step towards achieving our objective to expand Skytrofa's label beyond pediatric GHD and expand its reach to address new groups of patients," Ascendis Chief Executive Jan Mikkelsen said.
The application is based on results from a trial that compared the efficacy and safety of weekly TransCon hGH with a weekly placebo and daily human growth hormone in adults with growth hormone deficiency.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
December 12, 2024 17:21 ET (22:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。